Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Walter Morton who wrote (2473)	9/9/1999 7:45:00 PM
From: John Metcalf	Read Replies (2) \| Respond to of 2742

It's probably futile now to speculate on what this may be worth. Still, if you want to untangle who owns what, here are some links: Biotech Australia Pty, Ltd. Patent for human PAI-2 and for variants of human PAI-2. patents.ibm.com patents.ibm.com Cistron's rights probably derive from patents.ibm.com CIST's arrangements with Biotech Aus are described in the 10-K, June 98: In May 1993, Cistron granted an exclusive sublicense to Biotech Australia Pty. Limited ("Biotech"), a jointly owned subsidiary of Hoechst A.G. and Hoecsht Australia Ltd., to make, use and sell plasminogen activator inhibitor ("PAI-2") protein in the U.S. using technology contained in Cistron's PAI-2 DNA patent. Cistron has recently initiated development of a PAI-2 assay, using Biotech's reagents, which, if successfully developed, Cistron would sell to the North American research market.